Last reviewed · How we verify
MSP 3 Long Synthetic Peptide
At a glance
| Generic name | MSP 3 Long Synthetic Peptide |
|---|---|
| Sponsor | African Malaria Network Trust |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (PHASE1)
- Phase Ib Trial of MSP3 LSP in Children in Tanzania (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSP 3 Long Synthetic Peptide CI brief — competitive landscape report
- MSP 3 Long Synthetic Peptide updates RSS · CI watch RSS
- African Malaria Network Trust portfolio CI